Medicine, Health & Food

Medicine, Health & Food

Join as an Editor/Reviewer

The COVID-19 situation in Sudan. Plus, a possible life-saving intervention?

Volume: 61  ,  Issue: 1 , September    Published Date: 14 October 2020
Publisher Name: IJRP
Views: 102  ,  Download: 32
DOI: 10.47119/IJRP100611920201448


# Author Name
1 Hassan I. Osman
2 Meisa Elmamoun
3 Ahmed A. Elgamel


Purpose of review: To place forth a true understanding of the epidemiological characteristics of the novel coronavirus (COVID-19) in Sudan as well as propose a possible intervention that might decrease, if not completely deplete, the mortality rate. Recent findings: As of the 26th of August 2020, as per the JHU’s online world map covering the COVID-19 pandemic, the total number of confirmed cases worldwide was 23,918,447 with 819,945 deaths with the United States of America being the worst infected nation followed by Brazil and Mexico (based on the total number of deaths); in the Republic of the Sudan, the Federal Ministry of Health (FMOH) reported by the 23rd of August 2020, a total of 12,974 cases, 819 (~6.3%) of these patients had died, 6557 (~50.53%) had recovered and the remaining 5598 (~43.1%) were classified as “active” despite the nation being in experiencing a, at least partial, lockdown.


  • COVID-19
  • autoimmune
  • Sudan
  • References

    1. Sasmita Poudel Adhikari, et. al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infectious Diseases of Poverty (2020) 9:29


    1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020.
    2. WHO. Novel Coronavirus–China. 2020.

    https:// january-2020-novel-coronavirus-china/en. Accessed 4 April 2020.

    1. WHO. Novel Coronavirus-Japan (ex-China). 2020.

    http:// Accessed 5 April 2020

    1. Novel 2019 Coronavirus Genome 2020. Accessed 5 April 2020.
    2. WHO. Novel Coronavirus–China. 2020. Accessed 23 April 2020 
    3.  National Health Commission of People’s Republic of China. Prevent guideline of 2019-nCoV. 2020. Accessed 3 Feb 2020.
    4. CDC. 2019 Novel coronavirus, Wuhan, China. 2020. Accessed 3 Feb 2020
    5.  Zhang H, Kang Z, Gong H, Xu D, Wang J, Li Z, et al. The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes. bioRxiv. 2020; doi:
    6.  Goyal P, et. al. Clinical Characteristics of Covid-19 in New York City. N Engl J Med. 2020. DOI: 10.1056/NEJMc2010419
    7.  Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020. DOI: 10.1056/ NEJMoa2002032.
    8. Bangalore S, et. al. ST-Segment Elevation in Patients with Covid-19 — A Case Series. N Engl J Med. 2020. DOI: 10.1056/NEJMc2009020
    9. Zulfiqar AA, et al. Immune Thrombocytopenic Purpura in a Patient with Covid-19. N Engl J Med. 2020. DOI: 10.1056/NEJMc2010472
    10.  Chen L, et. al. Clinical Characteristics of Pregnant Women with Covid-19 in Wuhan, China. N Engl J Med. 2020. DOI: 10.1056/NEJMc2009226
    11. J. B. Moore, C. H. June, Science 10.1126/science.abb8925 (2020).
    12. G. Chen, D. Wu, W. Guo, Y. Cao, D. Huang, H. Wang, T. Wang, X. Zhang, H. Chen, H. Yu, X. Zhang, M. Zhang, S. Wu, J. Song, T. Chen, M. Han, S. Li, X. Luo, J. Zhao, Q. Ning, Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Invest. 137244 (2020). doi:10.1172/JCI137244 Medline
    13. Q. Ruan, K. Yang, W. Wang, L. Jiang, J. Song, Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 10.1007/s00134-020-05991-x (2020). doi:10.1007/s00134-020-05991-x Medline
    14. Ascierto PA, Fox B, Urba W, et al. Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. Journal for ImmunoTherapy of Cancer 2020;8:e000878. doi:10.1136/ jitc-2020-000878
    15. Xie P, Ma W, Tang H and Liu D (2020) Severe COVID-19: A Review of Recent Progress With a Look Toward the Future. Front. Public Health 8:189. doi: 10.3389/fpubh.2020.00189
    16.  Shimabukuro-Vornhagen et al., Cytokine Release Syndrome, Journal for ImmunoTherapy of Cancer (2018) 6:56
    17.  Tanaka T., Narazaki M., Kishimoto T., Immunotherapeutic implications of IL-6 blockade for cytokine storm, Immunotherapy (2016) 8(8), 959–970
    18.  Sheppard M, et. al. Tocilizumab (Actemra). HUMAN VACCINES & IMMUNOTHERAPEUTICS 2017, VOL. 13, NO. 9, 1972–1988
    19.  Mock JR, et. al. COVID-19: Clean up on IL-6. AJRCMB. 2020. 10.1165/rcmb.2020-0277LE